Background: Molecular pathological research offers new chances for the diagnostic and therapeutic management of malignant iris tumors. Besides immunohistological and polymerase chain reaction analyses further techniques, such as multiplex ligation-dependent probe amplification, microsatellite analyses and next-generation sequencing are able to detect various mutations in the tumor genome. Objective: An up to date review of new molecular pathological strategies for malignant iris tumors was carried out. Methods: This article provides a review of the recent literature based on a PubMed search and clinical experience with iris tumors. Results: The diagnostic characteristics and targeted treatment options are presented, exemplified by iris melanoma and iris carcinoma metastases. In iris melanomas, mutations in the GNA11 and GNAQ genes (in approximately 85% of the cases) seem to be important. Furthermore, the monosomy-3 status should be investigated in these tumors. In iris lymphomas, molecular pathological analyses are essential for an exact diagnosis. Detection of mutations in MYD88, BRAF, KLF2, ID3, TCF3, STAT3, RHo, TET2, IDH2, CXCR4, CD79B and DNMT3A are helpful. In particular, the detection of the CD20 antigen is of therapeutic relevance because this lymphoma subgroup responds well to rituximab, a CD20 antibody treatment. In iris carcinoma metastases, investigations for mutations are helpful because then a targeted treatment seems to be possible. Conclusion: Molecular pathological analyses will become essential in the future management of iris tumors because they play a key role towards a personalized treatment approach.
|Translated title of the contribution||New molecular pathological strategies for malignant iris tumors|
|Number of pages||8|
|Publication status||Published - 01.04.2019|
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)